论文部分内容阅读
目的评估草酸铂用于原发性肝癌术后化疗的疗效。方法本组为2003年至2005年6月对27例原发性肝癌接受了根治性切除,随后接受了以草酸铂为主的化疗方案治疗(XELOX和FOXFOL方案)临床研究。为了了解该方案疗效(CR、PR、SD、PD、OS和DFS),作者分别以RECIST标准和NCICTC标准评价疗效及毒性反应。结果26人获得可评估客观疗效。10例患者获得CR(38.46%),PR5例(12.23%),SD6例(23.08%),PD5例(12.23%)。中位无病生存时间(DFS):51.5周(13-68周),中位总生存时间:67周(16-95周)。总病情缓解率(ORR):57.7%。总体的毒副作用:I、II度骨髓抑制(55.1%),I、II度胃肠道反应(51.4%),I、II度肝功能损害(57.9%),I、II度周围神经病变(25.2%)。结论以草酸铂为主的联合化疗方案在原发性肝癌术后化疗的疗效较高,此化疗方案可能提高肝癌术后患者的总病情缓解率。安全性好。
Objective To evaluate the efficacy of oxaliplatin for postoperative chemotherapy of primary liver cancer. METHODS: Twenty-seven patients with primary liver cancer undergoing radical resection from 2003 to June 2005 were enrolled in this study, followed by a clinical study of oxaliplatin-based chemotherapy regimens (XELOX and FOXFOL regimens). To understand the efficacy of the regimen (CR, PR, SD, PD, OS, and DFS), the authors evaluated the efficacy and toxicity of the regimen against the RECIST and NCICTC criteria, respectively. Results 26 people can be assessed objective efficacy. Among the 10 patients, CR (38.46%), PR5 (12.23%), SD6 (23.08%) and PD5 (12.23%) were obtained. Median disease-free survival time (DFS): 51.5 weeks (13-68 weeks), median overall survival: 67 weeks (16-95 weeks). Total condition remission (ORR): 57.7%. The overall toxicities and side effects were: myelosuppression at I and II degrees (55.1%), gastrointestinal reactions at I and II degrees (51.4%), liver damage at I and II degrees (57.9%), peripheral neuropathy at I and II degrees (25.2% ). Conclusion Combined oxaliplatin-based chemotherapy in patients with primary liver cancer is more effective in postoperative chemotherapy. This chemotherapy regimen may improve the overall disease response rate of postoperative patients with liver cancer. Good safety.